-
A Russian state virology institute has started clinical trials of the country's second potential COVID-19 vaccine, injecting the first of five volunteers with a dose on July 27, as reported This is Money on Tuesday.
-
The next participant in the trial by the Vector virology institute in Siberia will receive a dose on July 30.
-
The trial is expected to include 100 volunteers between the ages of 18 and 60.
-
World Health Organization records show that Vector is working on six different potential COVID-19 vaccines.
-
Meanwhile, the Gamaleya Institute completed early clinical trials of an adenovirus-based vaccine earlier this month and expects to enter large-scale trials in August.
To read more NewsPoints articles, click here.
